The Modern Financial Terminal

Trusted by leading companies and financial institutions

BlackRock logoAllianz logoGoogle logoAnthropic logoBloomberg logoRevolut logoNASDAQ logoCoinbase logo
BlackRock logoAllianz logoGoogle logoAnthropic logoBloomberg logoRevolut logoNASDAQ logoCoinbase logo

Chugai Pharmaceutical Co Stock 4519.T

Price

8,400.00
Today +/-
+0.46
Today %
+1.02 %
P

Chugai Pharmaceutical Co stock price

Loading chart...
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Chugai Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Chugai Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Chugai Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Chugai Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Chugai Pharmaceutical Co Stock Price History

DateChugai Pharmaceutical Co Price
8,400.00 undefined
8,315.00 undefined
8,243.00 undefined
8,228.00 undefined
8,252.00 undefined
8,594.00 undefined
8,528.00 undefined
8,437.00 undefined
8,421.00 undefined
8,495.00 undefined
8,400.00 undefined
8,303.00 undefined
8,516.00 undefined
8,243.00 undefined
8,305.00 undefined
8,410.00 undefined
8,329.00 undefined
8,266.00 undefined

Chugai Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Chugai Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chugai Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chugai Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Chugai Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Chugai Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Chugai Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chugai Pharmaceutical Co’s growth potential.

Chugai Pharmaceutical Co Revenue, EBIT and net profit per share

DateChugai Pharmaceutical Co RevenueChugai Pharmaceutical Co EBITChugai Pharmaceutical Co Net Income
2027e1.44 T undefined0 undefined550.08 B undefined
2026e1.33 T undefined0 undefined488.18 B undefined
2025e1.25 T undefined0 undefined433.94 B undefined
20241.17 T undefined547.8 B undefined387.32 B undefined
20231.11 T undefined444.93 B undefined325.47 B undefined
20221.26 T undefined533.95 B undefined374.43 B undefined
2021999.76 B undefined428.24 B undefined303 B undefined
2020786.95 B undefined302.18 B undefined214.73 B undefined
2019686.18 B undefined214.51 B undefined157.56 B undefined
2018579.79 B undefined124.32 B undefined92.49 B undefined
2017534.2 B undefined98.93 B undefined72.71 B undefined
2016491.78 B undefined76.88 B undefined53.59 B undefined
2015498.84 B undefined86.78 B undefined61.13 B undefined
2014461.11 B undefined75.86 B undefined50.98 B undefined
2013423.65 B undefined78.74 B undefined50.9 B undefined
2012386.55 B undefined74.66 B undefined46.05 B undefined
2011373.52 B undefined62.43 B undefined35.23 B undefined
2010379.51 B undefined66.24 B undefined41.43 B undefined
2009428.95 B undefined82.62 B undefined56.63 B undefined
2008326.94 B undefined51.56 B undefined39.26 B undefined
2007344.81 B undefined66.7 B undefined40.06 B undefined
2006326.11 B undefined58.35 B undefined38.42 B undefined
2005327.16 B undefined79.17 B undefined53.41 B undefined

Chugai Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (T)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.170.040.180.190.190.190.20.20.210.240.230.290.330.330.340.330.430.380.370.390.420.460.50.490.530.580.690.7911.261.111.171.251.331.44
--77.52371.252.270.062.043.143.844.2912.13-1.9626.6011.02-0.325.73-5.1831.20-11.53-1.583.499.608.848.18-1.428.638.5318.3514.6827.0426.00-11.785.337.106.098.08
67.1667.2466.8668.0667.7667.8869.8169.4469.3866.7063.9862.1563.4959.1960.1861.1555.0457.2057.8356.5055.8752.7151.8449.5852.4254.6661.4265.2566.2262.1962.8771.1466.4262.6157.93
115.1125.9121.37126.35125.89128.66136.48140.98146.88158.35148.92183.13207.71193.04207.51199.91236.1217.09216.01218.4236.68243.03258.6243.84280.03316.94421.45513.48662.08783.48698.72832.76000
8.212.639.8111.589.758.058.7615.514.6-20.2328.3634.0353.4138.4240.0639.2656.6341.4335.2346.0550.950.9861.1353.5972.7192.49157.56214.73303374.43325.47387.32433.94488.18550.08
--67.93272.5917.95-15.76-17.438.8376.90-5.83-238.56-240.1820.0056.97-28.074.28-1.9944.24-26.84-14.9630.7010.520.1719.90-12.3235.6827.2070.3636.2941.1023.58-13.0819.0012.0412.5012.68
------------19.678.0010.0010.0012.0011.3314.3313.3314.0015.0017.3317.3318.3321.3329.6755.6760.0084.0080.0081.00157.00113.45126.75
0000000000000-59.3325020-5.5826.48-6.985.037.1415.5305.7716.3739.187.637.7840-4.761.2593.83-27.7411.72
0.740.740.820.890.880.860.860.890.891.171.671.671.661.661.641.641.631.631.631.631.641.641.641.641.641.641.641.651.651.651.651.65000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

Revenue and Growth

The Chugai Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Chugai Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (B)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (T)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (B)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (T)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (T)
OTHER EQUITY (B)
UNREAL. GAINS/LOSSES (B)
EQUITY (T)
LIABILITIES (B)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (B)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (T)
199319931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                 
75.4175.4164.3496.85121.2185.0589.8490.2662.1578.23117.8866.9297.32143.03150.23138.71125.48159.14135.91168.16213.63242.01231.98239.54216.28245.2251.6338.11378.62471.97503.11738.98996.35
77.8777.8770.8965.5964.1362.6163.5465.3268.1665.7597.26113.21104.03118.53105.69106.96108.4121.57113.39110.91115.99111.09141.32134.45140.7148.47150.78139.63195.63281.32436.38252.53258.34
0000000000000000000012.6617.318.5724.2726.7826.5328.7842.0157.7274.6977.967.8276.82
17.8117.8118.2119.5719.6422.2423.2923.125.9526.2740.8253.1657.9247.4461.5355.1978.7492.64104.88104.98108.41128.54139.57161.14185.44169.06159.36168.12183.89208.84292.21273.48240.07
14.8914.8914.723.924.64.053.617.1110.7912.520.5822.2115.6719.4520.2128.9531.7337.9532.3535.384.415.37.478.399.569.899.5811.8119.0426.8426.9433.6234.48
0.190.190.170.190.210.170.180.190.170.180.280.260.270.330.340.330.340.410.390.420.460.50.540.570.580.60.60.70.831.061.341.371.61
49.2349.2349.3956.2466.7775.8580.7180.2277.881.4493.9791.9790.0579.4685.1592.598.3593.6687.9582.93143.06140.45140.25153.55157.08171.57222.39265.31297.49352.11386.65420.7441.55
17.8317.8318.1416.0119.5817.4416.314.5354.0841.8720.6417.113.2618.4815.1516.8314.399.667.596.430000009.722.963.0311.7811.4712.5116.62
2.042.042.012.172.212.11.941.611.481.180.210.190.150.10.090.060.040.030.020.010000000000000
7.567.567.426.015.325.024.493.84.496.783.213.372.796.145.133.723.113.242.361.966.59.5111.2913.5119.321.0822.723.5423.8821.9725.1419.8617.87
8.268.268.227.997.757.526.716.226.256.3600000000000000000000000
13.4413.4413.4311.929.4913.8414.6428.9129.0228.8430.7237.0630.2523.8218.9416.0118.2822.6523.5622.7240.6743.0249.152.5751.1560.6964.6567.4376.1989.18109.96113.06126.29
98.3798.3798.62100.34111.11121.76124.79135.29173.12166.47148.76149.69136.51128124.46129.13134.16129.24121.48114.05190.23192.98200.63219.63227.53253.33319.46359.24400.59475.03533.22566.12602.33
0.280.280.270.290.320.30.310.320.340.350.430.410.410.460.460.460.480.540.510.530.650.70.740.790.810.850.921.061.241.541.871.932.21
                                                                 
21.1821.1821.1821.1821.1821.1821.1922.5523.9924.0368.2268.2470.5372.4472.8972.9572.9772.9772.9772.9772.9772.9772.9772.9772.9772.977373.0273.273.273.273.273.2
31.631.631.631.631.631.631.6133.3335.1435.1888.0888.190.3992.392.7592.892.8292.8292.8292.8264.6765.7767.3262.5763.564.8266.0467.0467.5968.2268.8169.3669.9
0.070.070.070.080.090.090.10.120.130.140.120.140.160.210.230.250.270.310.330.340.40.430.450.490.510.550.620.720.851.051.291.491.75
00000000-1.221.92-0.11-0.090.280.562.11.94-7.89-6.77-11.25-12.99-8.773.04-0.16-5.23-3.22-2.9-6.2-8.67-10.28-7.55-10.77-5.8811.62
000000005.212.531.032.342.413.783.242.761.351.641.340.841.873.74.766.64.866.074.930.530.40.09-0.210.16-0.15
0.120.120.120.130.140.150.150.170.190.20.280.30.330.380.40.420.430.470.480.490.530.570.60.630.650.690.760.850.981.191.421.631.9
18.4318.4317.4514.1613.411.9613.0211.110.6910.1616.9920.7119.1620.9928.1317.3328.7734.2619.4917.3541.835.9435.3941.1742.5338.4335.9347.7358.2897.2144.0554.2316.15
16.5416.5412.1415.0114.7118.1316.6917.2819.0719.2720.718.5222.5519.9117.3523.5325.5332.9621.5525.8426.827.1737.7437.9137.1841.8248.0854.8357.3365.0765.6794.6588.9
20.720.711.3420.9525.7214.6322.531721.817.7853.7417.0620.6437.5719.7828.5924.2333.2513.5325.6326.0834.5241.1953.8543.8242.5251.0869.45113.8158.6207.57132.36178.95
19.4619.4615.8317.857.575.834.024.023.813.6900000000000000000000000
000023.7909.64.650.3140.130.140.011000.3400.01000.040.040.030.130.140.130.137.266.656.556.436.986.37
75.1475.1456.7667.9685.1850.5565.8554.0555.6991.0391.5756.363.3678.4665.2669.7978.52100.4854.5868.8294.7297.67114.35133.06123.66122.9135.22179.27236.07327.42423.73288.22290.36
74.4474.4474.2273.8479.481.1271.4166.5166.2826.2711.9710.755.171.350.45000.01000.210.20.190.60.510.210.085.494.649.497.686.484.53
00000000.50.040.020.020.0200000000.19.9612.2110.7210.039.159.219.039.39.177.617.095.795.08
13.6313.6313.1813.7616.2517.2815.7428.1526.9230.1242.840.520.616.624.83.342.935.374.045.4811.2713.9416.5316.4426.4727.2618.6910.875.626.156.886.486.91
88.0688.0687.4187.695.6598.487.1695.1693.2456.4154.7851.2725.787.975.253.352.935.384.045.5921.4526.3427.4327.0736.1336.6727.825.6619.4323.2621.6418.7516.52
163.2163.2144.17155.56180.83148.94153149.21148.93147.44146.35107.5789.1486.4370.5173.1481.45105.8658.6274.4116.16124.01141.78160.13159.79159.58163.02204.93255.5350.68445.37306.97306.87
0.280.280.270.290.320.30.30.320.340.350.420.410.420.460.470.490.510.580.540.570.640.70.740.790.810.850.921.061.241.541.871.932.21
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Chugai Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Chugai Pharmaceutical Co's financial health and stability.

Assets

Chugai Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Chugai Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Chugai Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Chugai Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1999200020012002null200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00000000000000000000000303374.430
000000000000000000000030.3830.8731.430
00000000000000000000000000
43.1329.9450.7337.9137.9116.9961.284.7175.0681.2969.590.5654.4481.41102.8-23.61-36.79-18.1-38.675.5-1.22-8.08-132.71-187.4-328.81123.28
000000000000000000000092.64133.17167.060
-1,019-1,057-959-426-426-215-337-297-265-176-134-19-6-4-400000003448580
-16.31-10.88-20.21-10.57-10.57-53.65-10.95-19.75-34.26-20.75-30.09-24.08-38.87-11.81-25.5-23.83-25.22-29.14-25.34-22.66-31.57-34.7866.79104.07152.08-176.07
25.81829.5726.9226.92-36.8749.9164.6640.5460.3639.2866.4615.5769.5977.353.5237.0362.9238.79107.62119.07206.64205.04279.63244.11409.92
-13,897-10,606-14,527-14,366-14,366-15,973-11,746-9,102-21,322-22,596-25,222-16,068-13,565-11,238-15,053-14,964-19,167-25,263-36,422-44,526-77,671-61,177-61,411-72,866-71,239-74,258
0.48-7.69-29.29-16.03-16.0314.41-15.21-35.46-29.37-7.51-14.12-20.26-20.19-15.13-54.77-13.21-14.35-45.27-10.11-36.72-74.06-81.74-98.31-118.93-145.99-37.29
14.372.91-14.77-1.66-1.6630.39-3.47-26.36-8.0515.0911.1-4.19-6.63-3.9-39.721.754.82-20.0126.327.813.61-20.56-36.9-46.06-74.7636.97
00000000000000000000000000
-9,660-4,858-467-13,767-13,767-1,302-11-1,00000-3040000000000-8,861-8,432-9,031-7,599-7,868
2.692.81-0.0737.2937.29-5.87-1.6800.02-27.52-0.07-1.13-0.01-00.040.811.211.410.510.90.980.710.410.310.240.21
-9.81-5.5-4.956.556.55-11.58-13.72-12.56-18.8-47.17-18.36-22.25-23.05-24.55-22.72-23.17-24.39-28.47-33.42-29.56-35.01-66.87-99.5-107.41-145.64-139.33
-2.00-2.00-8.00-12,510.00-12,510.00-7.00-5.00-3.00--1,519.00-1,651.00-1,506.00-1,285.00-1,150.00-983.00-1,103.00-1,075.00-1,498.00-2,244.00-411.00-981.00-2,351.00-33.00-47.00-58.00-81.00
-2,834-3,444-4,409-4,457-4,457-4,404-12,021-11,558-18,821-18,136-16,335-19,619-21,759-23,396-21,778-22,874-24,520-28,375-31,677-30,054-35,010-56,370-91,442-98,644-138,220-131,594
16.015.33-3.7417.1717.17-34.3721.1617-6.055.39-3.0723.82-29.3329.330.93120.5898.0297.8396.46168.48159.64306.58348.62525.79530.29699.23
11,9047,39615,04012,5500-52,84138,16855,55919,21537,76514,05350,3922,00758,35362,24638,55717,86737,6552,36563,09741,403145,464143,625206,760172,873335,666
00000000000000000000000000

Chugai Pharmaceutical Co stock margins

The Chugai Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chugai Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chugai Pharmaceutical Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Chugai Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Chugai Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Chugai Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Chugai Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chugai Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chugai Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chugai Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Chugai Pharmaceutical Co Margin History

Chugai Pharmaceutical Co Gross marginChugai Pharmaceutical Co Profit marginChugai Pharmaceutical Co EBIT marginChugai Pharmaceutical Co Profit margin
2027e71.14 %0 %38.26 %
2026e71.14 %0 %36.7 %
2025e71.14 %0 %34.61 %
202471.14 %46.8 %33.09 %
202362.87 %40.03 %29.29 %
202262.19 %42.39 %29.72 %
202166.22 %42.83 %30.31 %
202065.25 %38.4 %27.29 %
201961.42 %31.26 %22.96 %
201854.66 %21.44 %15.95 %
201752.42 %18.52 %13.61 %
201649.58 %15.63 %10.9 %
201551.84 %17.4 %12.25 %
201452.71 %16.45 %11.06 %
201355.87 %18.59 %12.01 %
201256.5 %19.32 %11.91 %
201157.83 %16.71 %9.43 %
201057.2 %17.45 %10.92 %
200955.04 %19.26 %13.2 %
200861.15 %15.77 %12.01 %
200760.18 %19.34 %11.62 %
200659.19 %17.89 %11.78 %
200563.49 %24.2 %16.33 %

Chugai Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Chugai Pharmaceutical Co earnings per share therefore indicates how much revenue Chugai Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Chugai Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chugai Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chugai Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chugai Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chugai Pharmaceutical Co Revenue, EBIT and net profit per share

DateChugai Pharmaceutical Co Sales per ShareChugai Pharmaceutical Co EBIT per shareChugai Pharmaceutical Co Earnings per Share
2027e873.56 undefined0 undefined334.27 undefined
2026e808.29 undefined0 undefined296.65 undefined
2025e761.86 undefined0 undefined263.69 undefined
2024711.34 undefined332.88 undefined235.36 undefined
2023675.4 undefined270.39 undefined197.8 undefined
2022765.63 undefined324.52 undefined227.57 undefined
2021607.67 undefined260.29 undefined184.17 undefined
2020478.36 undefined183.69 undefined130.53 undefined
2019417.25 undefined130.44 undefined95.81 undefined
2018352.72 undefined75.63 undefined56.27 undefined
2017325.28 undefined60.24 undefined44.28 undefined
2016299.68 undefined46.85 undefined32.66 undefined
2015304.09 undefined52.9 undefined37.26 undefined
2014281.53 undefined46.32 undefined31.13 undefined
2013259.02 undefined48.14 undefined31.12 undefined
2012236.65 undefined45.71 undefined28.19 undefined
2011228.71 undefined38.23 undefined21.57 undefined
2010232.4 undefined40.56 undefined25.37 undefined
2009262.52 undefined50.56 undefined34.66 undefined
2008199.95 undefined31.54 undefined24.01 undefined
2007209.89 undefined40.6 undefined24.39 undefined
2006195.94 undefined35.06 undefined23.08 undefined
2005196.6 undefined47.58 undefined32.1 undefined

Chugai Pharmaceutical Co business model

Chugai Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1925. It is headquartered in Tokyo and employs over 7,500 employees worldwide. Chugai is one of the largest pharmaceutical companies in Japan and has become a global company with a strong research and development department in recent decades. The business model of Chugai is based on the development and production of drugs for various medical conditions, with a focus on cancer therapy. However, Chugai also has drugs for other medical conditions in its portfolio, such as rheumatism, asthma, and diabetes. The company specializes in research and development of biotechnological therapeutics and has focused on the study of biological agents. Chugai's goal is to improve people's lives and enhance patient care. Chugai is divided into several business units, each focusing on different areas of therapy. One of these areas is oncology. Chugai has a strong range of oncology products, for which it is a market leader in Japan. These include Avastin, an anti-angiogenesis drug for the treatment of colorectal, breast, lung, and kidney cancer, as well as Herceptin for the treatment of breast and gastric cancer, and Tarceva for treating bronchial carcinomas. Another important business area of Chugai is rheumatology. Here, Chugai offers various products such as Actemra, a monoclonal antibody against the interleukin-6 receptor used in rheumatoid arthritis, as well as Rituxan, an antibody against the CD20 antigen used in the treatment of lymphomas. In addition to drug development and manufacturing, Chugai also conducts research and development in the field of diagnostics. This is an important complement to the company's therapeutic portfolio. Chugai develops diagnostics to improve disease diagnosis. Another important area of Chugai is the outsourcing of research and development services. Chugai collaborates with many international pharmaceutical companies, offering its expertise and infrastructure in the development of new drugs. Chugai Pharmaceuticals is a significant player in global healthcare and aims to establish itself as a leading company in biological and cellular preparation research. The company invests significant resources in the exploration of new technologies to ensure sustainable therapy options. Chugai Pharmaceuticals has built a strong presence in the global market in recent years and will continue to play an important role in the future. Chugai Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Chugai Pharmaceutical Co SWOT Analysis

Helpful
Harmful
Internal

Strengths

Chugai Pharmaceutical Co Ltd has several key strengths:

  • Strong product portfolio: Chugai offers a diverse range of pharmaceutical products, including innovative drugs and treatments in various therapeutic areas.
  • Research and development capability: The company has a robust R&D division focused on developing new drugs and improving existing ones, which helps it stay competitive in the market.
  • Strong financial position: Chugai enjoys stable financial performance, which provides the company with the resources necessary for investment in research, development, and marketing.
  • Global presence: With a strong presence in both domestic and international markets, Chugai benefits from a broad customer base and geographic diversification.

Weaknesses

Despite its strengths, Chugai Pharmaceutical Co Ltd faces some weaknesses:

  • Dependency on key products: Chugai relies heavily on a few key products for a significant portion of its revenue, leaving it vulnerable to the potential failure or decline of those products.
  • Limited market share in some regions: In certain regions, Chugai faces strong competition from local and global pharmaceutical companies, limiting its market share and growth potential.
  • Regulatory challenges: Like any pharmaceutical company, Chugai is subject to strict regulations and approvals, which can delay product launches and impact its ability to capture market opportunities.
External

Opportunities

Chugai Pharmaceutical Co Ltd can leverage the following opportunities:

  • Expanding markets: Growing healthcare needs, particularly in emerging markets, present opportunities for Chugai to expand its customer base and increase sales.
  • Advancements in technology: Technological advancements enable Chugai to develop more effective and innovative drugs, leading to improved patient outcomes and market advantage.
  • Strategic alliances and partnerships: Collaborations with other pharmaceutical companies or research institutions can enhance Chugai's R&D capabilities and provide access to new markets or technologies.

Threats

Chugai Pharmaceutical Co Ltd should be cautious of the following threats:

  • Intense competition: The pharmaceutical industry is highly competitive, with many companies vying for market share. Chugai must continuously innovate and differentiate itself to mitigate the threat.
  • Pricing pressure: Increasing cost-containment measures by healthcare providers and governments may exert pressure on drug prices, potentially impacting Chugai's profitability.
  • Intellectual property risks: The company's patents and intellectual property are subject to expiration and infringement risks, which could lead to loss of exclusivity and revenue.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Chugai Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Chugai Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Chugai Pharmaceutical Co shares outstanding

The number of shares was Chugai Pharmaceutical Co in 2025 — This indicates how many shares 1.646 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Chugai Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chugai Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chugai Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chugai Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chugai Pharmaceutical Co stock splits

In Chugai Pharmaceutical Co's history, there have been no stock splits.

Chugai Pharmaceutical Co dividend history and estimates

In 2025, Chugai Pharmaceutical Co paid a dividend amounting to 157 undefined. Dividend means that Chugai Pharmaceutical Co distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

Dividend Overview

The dividend per year chart for Chugai Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Chugai Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Chugai Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Chugai Pharmaceutical Co Dividend History

DateChugai Pharmaceutical Co Dividend
2027e126.75 undefined
2026e113.45 undefined
2007e5 undefined
2006e4 undefined
2025157 undefined
202481 undefined
202380 undefined
202284 undefined
202160 undefined
202055.67 undefined
201929.67 undefined
201821.33 undefined
201718.33 undefined
201617.33 undefined
201517.33 undefined
201415 undefined
201314 undefined
201213.33 undefined
201114.33 undefined
201011.33 undefined
200912 undefined
200810 undefined
2007e5 undefined
2006e4 undefined
200519.67 undefined

Chugai Pharmaceutical Co dividend payout ratio

In 2025, Chugai Pharmaceutical Co had a payout ratio of 37.25%. The payout ratio indicates the percentage of the company's profits that Chugai Pharmaceutical Co distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Chugai Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Chugai Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Chugai Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Chugai Pharmaceutical Co Payout Ratio History

DateChugai Pharmaceutical Co Payout ratio
2027e37.92 %
2026e38.24 %
2025e37.25 %
202438.26 %
202339.23 %
202234.28 %
202141.27 %
202042.14 %
201948.71 %
201842.65 %
201746.67 %
201653.07 %
201546.52 %
201451.4 %
201348.2 %
201247.3 %
201161.81 %
201052.56 %
200932.7 %
200847.2 %
200741 %
200651.99 %
200536.33 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Chugai Pharmaceutical Co.

Chugai Pharmaceutical Co Earnings Calls

Chugai Pharmaceutical Co Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/25/202446.16 244.93 B 2024 Q1
1/31/202451.02 291.41 B 2023 Q4
7/19/202341.87 234.16 B 2023 Q2
4/24/202339 230.61 B 2023 Q1
2/1/202360.42 412.65 B 2022 Q4
10/24/202247.79 271.28 B 2022 Q3
7/21/202246.37 260.36 B 2022 Q2
4/25/202254.84 286.99 B 2022 Q1
2/3/202255.21 302.6 B 2021 Q4
10/22/202144.52 242.3 B 2021 Q3
1
2
3
4
5
...
6

Chugai Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/202572.65 67.58  (-6.98 %)2025 Q3
6/30/202574.83 59.04  (-21.11 %)2025 Q2
3/31/202549.3 59.09  (19.86 %)2025 Q1
12/31/202459.82 55.64  (-6.99 %)2024 Q4
9/30/202462.11 66.55  (7.15 %)2024 Q3
6/30/202453.57 67.98  (26.91 %)2024 Q2
3/31/202447.34 45.22  (-4.48 %)2024 Q1
12/31/202350.52 55.43  (9.73 %)2023 Q4
9/30/202349.39 47.15  (-4.54 %)2023 Q3
6/30/202341.88 50.57  (20.76 %)2023 Q2
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Chugai Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

93/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

80

Environment

Scope 1 - Direct Emissions
51,143
Scope 2 - Indirect emissions from purchased energy
65,695
Scope 3 - Indirect emissions within the value chain
981,329
Total CO₂ emissions
116,838
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees37.3
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Chugai Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
61.11129 % F. Hoffman La Roche, Ltd.1,005,670,0000
2.91199 % Nomura Asset Management Co., Ltd.47,920,828-383,829
1.42840 % Nikko Asset Management Co., Ltd.23,506,289-300,400
1.35805 % Daiwa Asset Management Co., Ltd.22,348,49639,399
1.27818 % The Vanguard Group, Inc.21,034,199-3,200
1.25332 % BlackRock Institutional Trust Company, N.A.20,625,047262,100
0.60917 % Mitsubishi UFJ Asset Management Co., Ltd.10,024,749-9,505
0.60688 % JPMorgan Securities Japan Co., Ltd.9,987,0009,987,000
0.58497 % Wellington Management Company, LLP9,626,4550
0.57369 % T. Rowe Price Associates, Inc.9,440,801270,700
1
2
3
4
5
...
10

Chugai Pharmaceutical Co Executives and Management Board

Mr. Osamu Okuda

(61)
Chugai Pharmaceutical Co President, Chief Executive Officer, Representative Director (since 2014)
Compensation 375 M

Mr. Iwaaki Taniguchi

(57)
Chugai Pharmaceutical Co Senior Executive Officer, Chief Financial Officer, Senior Manager of Finance, Director (since 2022)

Dr. Hitoshi Iikura

(54)
Chugai Pharmaceutical Co Senior Executive Officer, Chief Director of Translational Research, Director (since 2022)

Mr. Junichi Ebihara

Chugai Pharmaceutical Co Senior Executive Officer

Mr. Shinji Hidaka

Chugai Pharmaceutical Co Senior Executive Officer
1
2
3
4
...
5

Most common questions regarding Chugai Pharmaceutical Co

What values and corporate philosophy does Chugai Pharmaceutical Co represent?

Chugai Pharmaceutical Co Ltd represents values of innovation, integrity, and patient-centricity as a leading Japanese pharmaceutical company. With a strong corporate philosophy, Chugai is committed to improving the quality of life for patients through the discovery and development of innovative medicines. Adopting a patient-focused approach, Chugai strives to address unmet medical needs and provide effective therapies across various therapeutic areas. By combining cutting-edge R&D capabilities with a global perspective, Chugai aims to bring about advancements in healthcare and contribute to society through its valuable healthcare solutions.

In which countries and regions is Chugai Pharmaceutical Co primarily present?

Chugai Pharmaceutical Co Ltd is primarily present in Japan.

What significant milestones has the company Chugai Pharmaceutical Co achieved?

Chugai Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. One notable accomplishment was obtaining regulatory approval for its breakthrough oncology drug, Trastuzumab. This medication revolutionized the treatment of HER2-positive breast cancer, providing patients with improved outcomes and survival rates. Furthermore, Chugai Pharmaceutical Co Ltd successfully developed and launched other innovative therapies, like Actemra/RoActemra, a treatment for rheumatoid arthritis. The company's focus on research and development has allowed them to continuously bring groundbreaking drugs to the market, benefiting patients worldwide. Chugai Pharmaceutical Co Ltd continues to strive for excellence in the pharmaceutical industry, consistently pushing boundaries in therapeutic advancements.

What is the history and background of the company Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co Ltd is a leading Japanese pharmaceutical company with a rich history and background. Established in 1925, Chugai has been committed to developing innovative medications to improve patients' lives. With its headquarters in Tokyo, Chugai has expanded its presence globally and is known for its expertise in biotechnology and oncology research. The company has collaborated with international partners to push the boundaries of medical science and deliver breakthrough treatments. Chugai Pharmaceutical Co Ltd's dedication to research and development has positioned it as a reputable player in the pharmaceutical industry, with a focus on providing innovative healthcare solutions worldwide.

Who are the main competitors of Chugai Pharmaceutical Co in the market?

The main competitors of Chugai Pharmaceutical Co Ltd in the market are Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, and Astellas Pharma Inc.

In which industries is Chugai Pharmaceutical Co primarily active?

Chugai Pharmaceutical Co Ltd is primarily active in the biopharmaceutical industry.

What is the business model of Chugai Pharmaceutical Co?

The business model of Chugai Pharmaceutical Co Ltd focuses on research, development, manufacturing, and commercialization of innovative pharmaceutical products. Chugai Pharmaceutical specializes in the areas of oncology, bone and joint diseases, renal diseases, and autoimmune diseases among others. Through its extensive research and collaboration with global partners, the company aims to discover and provide innovative solutions to improve patients' quality of life and meet the unmet medical needs. With a commitment to enhancing healthcare globally, Chugai Pharmaceutical is dedicated to bringing forth cutting-edge therapies that contribute to society's well-being.

What is the P/E ratio of Chugai Pharmaceutical Co 2026?

The Chugai Pharmaceutical Co P/E ratio is 28.32.

What is the P/S ratio of Chugai Pharmaceutical Co 2026?

The Chugai Pharmaceutical Co P/S ratio is 10.39.

What is the Quality Investing of Chugai Pharmaceutical Co?

The Quality Investing for Chugai Pharmaceutical Co is 10/10.

What is the revenue of Chugai Pharmaceutical Co 2026?

The expected Chugai Pharmaceutical Co revenue is 1.33 T JPY.

How high is the profit of Chugai Pharmaceutical Co 2026?

The expected Chugai Pharmaceutical Co profit is 488.18 B JPY.

What is the business model of Chugai Pharmaceutical Co

Chugai Pharmaceutical Co Ltd is a Japanese company specializing in the discovery, development, manufacturing, and marketing of pharmaceuticals. It was founded in 1925 and is headquartered in Tokyo. Chugai has three main business areas: 1) Pharma, focusing on research and development of innovative drugs for diseases such as cancer and rheumatoid arthritis; 2) Diagnostics, manufacturing diagnostic kits to support cancer diagnosis and monitoring services; and 3) Alliances and partnerships, collaborating with other companies and academic institutions on research and development projects. Chugai places great emphasis on quality in drug manufacturing and continuously strives to optimize its R&D activities to develop therapies that meet the needs of its customers.

What is the Chugai Pharmaceutical Co dividend?

Chugai Pharmaceutical Co pays a dividend of 78 JPY distributed over payouts per year.

How often does Chugai Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Chugai Pharmaceutical Co or the company does not pay out a dividend.

What is the Chugai Pharmaceutical Co ISIN?

The ISIN of Chugai Pharmaceutical Co is JP3519400000.

What is the Chugai Pharmaceutical Co WKN?

The WKN of Chugai Pharmaceutical Co is 857216.

What is the Chugai Pharmaceutical Co ticker?

The ticker of Chugai Pharmaceutical Co is 4519.T.

How much dividend does Chugai Pharmaceutical Co pay?

Over the past 12 months, Chugai Pharmaceutical Co paid a dividend of 81 JPY . This corresponds to a dividend yield of about 0.96 %. For the coming 12 months, Chugai Pharmaceutical Co is expected to pay a dividend of 126.75 JPY.

What is the dividend yield of Chugai Pharmaceutical Co?

The current dividend yield of Chugai Pharmaceutical Co is 0.96 %.

When does Chugai Pharmaceutical Co pay dividends?

Chugai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of , , , .

How secure is the dividend of Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Chugai Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 126.75 JPY are expected. This corresponds to a dividend yield of 1.51 %.

In which sector is Chugai Pharmaceutical Co located?

Chugai Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chugai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chugai Pharmaceutical Co from amounting to 50 JPY, you needed to have the stock in your portfolio before the ex-date on .

When did Chugai Pharmaceutical Co pay the last dividend?

The last dividend was paid out on .

What was the dividend of Chugai Pharmaceutical Co in the year 2025?

In the year 2025, Chugai Pharmaceutical Co distributed 81 JPY as dividends.

In which currency does Chugai Pharmaceutical Co pay out the dividend?

The dividends of Chugai Pharmaceutical Co are distributed in JPY.

All fundamentals about Chugai Pharmaceutical Co

Our stock analysis for Chugai Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chugai Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.